Price
No data yet.
Social Signal Score
50
5d
50
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1
Revenue
$0.00Jun 2021Mar 2026
Company Profile
- CEO
- Jody Aufrichtig
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 0
- Beta
- 1.31
- Country
- CA
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -74.24
Financials
Revenue
$0.00-100.0%Net Income
$-163.3KEBITDA
$-159.9KFree Cash Flow
$-412.7KEPS (diluted)
$-0.01Shares Outstanding (diluted)
15.64M-81.7%Operating Expenses
$159.9KR&DSG&A
Cash & Debt
$441.1KCash & investmentsTotal debt
Return of Capital
$0.00BuybacksDividends
Quote
Day Range
$0.13 – $0.14
52-Week Range
$0.10 – $0.14
Volume
$100.00
Market Cap
$2.25M
50-Day Avg
$0.13
200-Day Avg
$0.13
Prev Close
$0.13
Open
$0.13
Valuation & Ratios
P/E Ratio
-4.47
EPS
$-0.04
P/B Ratio
3.86
P/S Ratio
0.00
Debt/Equity
0.00
Current Ratio
5.95
Dividend Yield
+0.0%
Gross Margin
+0.0%
Returns & Efficiency
Return on Equity
-86.2%
Return on Assets
-71.7%
FCF Yield
-37.0%
EV/EBITDA
-2.56
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-587.1K | $-0.04 |
| 2025 | $0.00 | $-400.2K | $-0.04 |
| 2024 | $0.00 | $-69.45M | $-0.52 |
| 2023 | $0.00 | $-6.08M | $-0.07 |
| 2022 | $0.00 | $-4.60M | $-0.05 |
| 2021 | $0.00 | $-92.5K | $-0.00 |
| 2020 | $0.00 | $-19.1K | $-0.01 |
| 2019 | $0.00 | $-13.3K | $-0.02 |
| 2018 | $0.00 | $-20.0K | $-0.04 |
| 2017 | $0.00 | $-54.8K | $-0.11 |
| 2016 | $0.00 | $-14.7K | $-0.03 |
Valuation
PSYGFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Aug 18Aug 18
Social Signal Score
50
5d
50
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1
Mentions (1)
- Newsglobenewswire.com·19h ago·Neutral
Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built
View source ↗